Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Blood

Volumn 125, Issue 8, 2015, Pages 1236-1243

  Gopal, Ajay K ^a   Chen, Robert ^b   Smith, Scott E ^c   Ansell, Stephen M ^d   Rosenblatt, Joseph D ^e   Savage, Kerry J ^f   Connors, Joseph M ^f   Engert, Andreas ^g   Larsen, Emily K ^h   Chi, Xuedong ⁱ   Sievers, Eric L ^h   Younes, Anas ^j  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF MIAMI   (United States)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^h SEATTLE GENETICS INC   (United States)

ⁱ TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; ANTIBODY CONJUGATE; CAC10-VCMMAE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER THERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MALE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMIC THERAPY; TREATMENT RESPONSE; AUTOTRANSPLANTATION; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOTHERAPY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; RECURRENT DISEASE; REMISSION; SURVIVAL; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84923319448     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-595801     Document Type: Article

References (32)

1. Sureda A, Arranz R, Iriondo A, et al; Grupo Español de Linformas/Transplante Autólogo deMédulaOsea Spanish Cooperative Group. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group. J Clin Oncol. 2001;19(5):1395-1404.
2. Sureda A, Constans M, Iriondo A, et al; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea Cooperative Group. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol. 2005; 16(4):625-633.
3. Arai S, Fanale M, DeVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54(11):2531-2533.
4. Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology (Am Soc Hematol Educ Program). 2008;326-333.
5. Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study: a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97(2): 310-317.
6. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
7. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5): 579-586.
8. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34(2):187-220.
9. Bestawros A, Foltz L, Srour N, Savage KJ, Connors JM. Patients' and physicians' roles in detecting recurrent Hodgkin lymphoma following complete remission. Ann Oncol. 2013;24(5): 1359-1363.
10. Dryver ET, Jernström H, Tompkins K, Buckstein R, Imrie KR. Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value. Br J Cancer. 2003;89(3): 482-486.
11. El-Galaly TC, Mylam KJ, Brown P, et al. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica. 2012;97(6): 931-936.
12. Gerlinger M, Rohatiner AZ, Matthews J, Davies A, Lister TA, Montoto S. Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management. Haematologica. 2010;95(7): 1130-1135.
13. Guadagnolo BA, Punglia RS, Kuntz KM, Mauch PM, Ng AK. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol. 2006;24(25):4116-4122.
14. Radford JA, Eardley A, Woodman C, Crowther D. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ. 1997;314(7077): 343-346.
15. Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol. 1997; 15(3):1123-1130.
16. Horning S, Fanale M, deVos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort. Ann Oncol. 2008;19(suppl 4):118.
17. Sureda A, Robinson S, Canals C, et al. Reducedintensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(3):455-462.
18. Sobol U, Rodriguez T, Smith S, et al. Sevenyear follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease. Leuk Lymphoma. 2014;55(6): 1281-1287.
19. Sarina B, Castagna L, Farina L, et al; Gruppo Italiano Trapianto di Midollo Osseo. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115(18): 3671-3677.
20. Robinson SP, Sureda A, Canals C, et al; Lymphoma Working Party of the EBMT. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94(2):230-238.
21. Devetten MP, Hari PN, Carreras J, et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009;15(1):109-117.
22. Chen R, Palmer JM, Popplewell L, et al. Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Ann Hematol. 2011;90(7):803-808.
23. Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1279-1287.
24. Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008;14(4):418-425.
25. Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008; 93(2):257-264.
26. Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006;12(2):172-183.
27. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365(9475): 1934-1941.
28. Chen R, Forman S, Palmer JM, et al. Two-year follow-up of patients with relapsed/refractory hodgkin treated with brentuximab vedotin prior to reduced intensity allogeneic hematopoietic cell transplantation [abstract]. Hematol Oncol. 2013; 31(S1):a140.
29. Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reducedintensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012; 119(26):6379-6381.
30. Garciaz S, Coso D, Peyrade F, et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. Hematol Oncol. 2014;32(4):187-191.
31. Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD301 lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013;98(4):611-614.
32. Illidge T, Bouabdallah R, Chen R, et al. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma. 2014;1-34.